NEW YORK (GenomeWeb News) – Molecular diagnostics firm Biodesix said on Tuesday that it has received certification from the New York State Department of Health to offer its VeriStrat serum proteomic test.
As a result, the test, which is to help guide doctors in the treatment of patients with non-small cell lung cancer, is available in all 50 states. The test is performed in Biodesix's CLIA laboratory.
A Biodesix officially recently told GenomeWeb Daily News that the company plans to pursue partnerships with drug manufacturers to broaden adoption of the Veristrat test. It also plans to pursue clearance from the US Food and Drug Administration for the test.
In November, the company announced it raised $7.1 million in a Series C round.